Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high gleason grade prostate carcinoma

Cancer

Volumn 83, Issue 5, 1998, Pages 989-1001

  Ragde, Haakon ^a,d   Elgamal, Abdel Aziz A ^a   Snow, Peter B ^b   Brandt, Jeff ^b   Bartolucci, Alfred A ^c   Nadir, Brad S ^a   Korb, Leroy J ^a  

^a NORTHWEST HOSPITAL   (United States)

^b Xiam Inc   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Urology Resource Center   (United States)

Author keywords

Brachytherapy; Deferred treatment; Disease free survival; External beam irradiation; Iodine 125; Neural network; Prostate carcinoma; Prostate specific antigen; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; BONE METASTASIS; CANCER GRADING; CANCER LOCALIZATION; CANCER SURVIVAL; ECHOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RADIOISOTOPE THERAPY;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; ULTRASONOGRAPHY;

EID: 0032167961     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980901)83:5<989::AID-CNCR26>3.0.CO;2-Q     Document Type: Article

References (49)

1. Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, et al. Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. J Urol 1994;152:1737-40.
2. Crawford ED, DeAntoni EP. PSA as a screening test for prostate cancer. Urol Clin North Am 1993;20:637-46.
3. Mettlin CJ, Murphy GP, Rosenthal DS, Menck HR. The National Cancer database report on prostate cancer following the peak in incidence rates in the United States. Cancer In press.
4. Whitmore WF, Hilaris B, Grabstald H. Retropubic implantation of iodine 125 in the treatment of prostatic cancer. J Urol 1972;108:918-20.
5. Elkin D, Kim J, Constable WC. Anatomic localization of radioactive gold seeds of the prostate by computer-aided tomography. Comput Tomogr 1981;5:89-93.
6. Gore RM, Moss AA. Value of computer tomography in interstitial 125 Iodine brachytherapy of prostatic carcinoma. Radiology 1983;146:453-8.
7. Mouli K, Sharifi R, Ray P, Baumgartner G, Guinan P. Prostatorectal fistula associated with Iodine seed radiotherapy. J Urol 1983;129:387-8.
8. Watanabe H, Igari D, Tanahashi Y, Harada K, Saitoh M. Transrectal ultrasonotomography of the prostate. J Urol 1975;114:734-9.
9. Holm HH, Juul N, Pedersen JF, Hansen H, Stroyer I. Transperineal Iodine-125 seed implantation in prostate cancer guided by transrectal ultrasonography. J Urol 1983;130:283-6.
10. Porrazzo MS, Hilaris BS, Moorthy CR, Tchelebi AE, Mostoras CA, Shih LL, et al. Permanent interstitial implantation using palladium-103. The New York Medical College preliminary experience. Int J Radiat Oncol Biol Phys 1992;23:1033.
11. Wannenmacher M, Sommerkamp H, Knufermann H. Die interstitielle Strahlentherapie in der Behandlung des Prostatakarzinoms. Dtsch Arztebl 1979;76:1371-6.
12. Holm HH, Kristensen JK, editors. Ultrasonically guided puncture technique. Copenhagen: Munksgaard and Baltimore: University Park Press, 1980.
13. Ragde H, Blasko JC, Grimm PD, Kenny GM, Sylvester J, Hoak DC, et al. Brachytherapy for clinically localized prostate cancer: results at 7-and 8-year follow-up. Semin Surg Oncol 1997;13:438-43.
14. Stone NN, Forman JD, Sogani PC, et al. Transrectal ultrasonography and I-125 implantation in patients with prostate cancer. J Urol 1988;139:604 [abstract].
15. Stock RG, Stone NN, DeWyngaert JK. PSA findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate cancer. Presented at: Proceedings of the American Radium Society 78th Annual Meeting, Paris, France, 1995; 58.
16. Grado GL, Larson TR, Collins JM. Fluoroscopic and ultrasound guided prostate implant: Technique and experience at Mayo Clinic Scottsdale [abstract]. Presented at: American Brachytherapy Society, 18th Annual Meeting, Scottsdale, Arizona, December 6-8, 1995:10 [abstract].
17. Dattoli MJ, Wasserman SG, Hoval JM, et al. Conformal brachytherapy boost to external beam irradiation for localized high risk prostate cancer [abstract]. Int J Radiat Oncol Biol Phys 1995;32:251.
18. Kaye KW, Olson DJ, Payne JT. Detailed preliminary analysis of 125 iodine implantation for localized prostate cancer using percutaneous approach. J Urol 1995;153:1020.
19. Ragde H, Blasko JC, Schumacher D. Use of transrectal ultrasound in transperineal Iodine-125 seeding for prostate cancer: methodology. J Endourol 1989;3:209-18.
20. Snow PB, Smith DS, Catalona WJ. Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. J Urol 1994;152:1923-6.
21. Sobin LH, Wittekind C, editors. UICC (Union Internationale Against Cancer): TNM classification of malignant tumors. 5th edition. New York: Wiley-Liss, 1997:170-3.
22. Ragde H, Blasko JC, Grimm PD, Kenny GM, Sylvester JE, Hoak DC, et al. Interstitial Iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997;80:442-53.
23. Zietman AL, Shipley WU, Coen JJ. Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen follow-up. J Urol 1994;152:1806-12.
24. Zelefsky MJ, Leibel SA, Wallner KE, Whimore WF, Fuks Z. Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostate cancer. J Clin Oncol 1995;13:459-63.
25. Schellhammer PF, El-Mahdi AM, Higgins EM, Schultheiss TE, Ladaga LE, Babb TJ. Prostate biopsy after definitive treatment by interstitial 125 Iodine implant or external beam radiation therapy. J Urol 1987;137:897-901.
26. Forman JD, Oppenheim T, Liu H, Montie J, McLaughlin PW, Porter AT. Frequency of residual neoplasm in the prostate following three-dimensional conformal radiotherapy. Prostate 1993;23:235-43.
27. Oefelein MG, Smith N, Carter M, Dalton D, Schaeffer A. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 349 radical prostatectomies. J Urol 1995;154:2128-31.
28. Adolfsson J, Steineck G, Hedlund P. Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series. Urology 1997;50:722-6.
29. Hanks GE, Martz KL, Diamond JJ. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 1988;15:1299-1305.
30. Leibel SA, Hanks GE, Kramer S. Patterns of care outcome studies: results of the National Practice in Adenocarcinoma of the Prostate. Int J Radiat Oncol Biol Phys 1984;10:401-9.
31. Kabalin JN, Hodge KK, McNeal JE, Freiha FS, Stamey TA. Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol 1989;142:326-31.
32. Kaplan ID, Cox RS, Bragshaw MA. Prostate specific antigen after external beam radiotherapy for prostate cancer: follow-up. J Urol 1993;149:519-25.
33. Kuban DA, EL-Mahdi AM, Schellhammer PF. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:307-16.
34. Zagars GK. The prognostic significance of a single serum prostate-specific antigen value beyond 6 months after radiation therapy for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1993;27:39-45.
35. Zietman AL, Coen JJ, Dallow KC, Shipley WU. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys 1995;32:287-92.
36. Hancock SL, Cox RS, Bagshaw MA. Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Standford University. J Urol 1995;154:1412-7.
37. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol 1995;154:456-9.
38. Rosenzweig KE, Morgan WR, Lytton B, Peschel RE. Prostate specific antigen following radiotherapy for local prostate cancer. J Urol 1995;153:1561-4.
39. Schellhammer PF, El-Mahdi AM, Wright GL, Kolm P, Ragle R. Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. Urology 1993;42:13-20.
40. Stamey TA, Ferrari MK, Schmid HP. The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J Urol 1993;150:1856-9.
41. Zagars GK. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol 1994;152:1786-91.
42. Zietman AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994; 151:640-5.
43. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837-42.
44. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152:1843-9.
45. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. Urol Clin North Am 1993;20:713-25.
46. Paulson DF. Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994;152: 1826-30.
47. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994; 152:1821-5.
48. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:1850-7.
49. Alexander RB, Maguire MG, Epstein JI, Walsh PC. Pathologic stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate. J Urol 1989;141:880-2.